A Phase I Study of INCB024360 Alone and In Combination With Pembrolizumab (MK-3475) in Patients With Advanced Solid Tumors (KEYNOTE-434)
Phase of Trial: Phase I
Latest Information Update: 08 Aug 2017
At a glance
- Drugs Epacadostat (Primary) ; Pembrolizumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Acronyms KEYNOTE-434
- Sponsors Merck Sharp & Dohme
- 02 Aug 2017 Planned End Date changed from 29 Dec 2017 to 31 Jan 2020.
- 02 Aug 2017 Planned primary completion date changed from 30 Nov 2017 to 31 Aug 2018.
- 10 Feb 2017 Planned End Date changed from 1 Aug 2017 to 1 Dec 2017.